|Bid||0.8590 x 1100|
|Ask||0.8800 x 3000|
|Day's Range||0.8201 - 0.8900|
|52 Week Range||0.6000 - 3.2500|
|Beta (3Y Monthly)||1.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 11, 2019 - Nov 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the article entitled “Vaginal tamoxifen for treatment of vulvar and vaginal atrophy: Pharmacokinetics and local tolerance in a rabbit model over 28 days” was published online in the International Journal of Pharmaceutics. The article highlights the positive findings from the animal study which include availability and local tolerability of vaginally delivered tamoxifen. DARE-VVA1 is a novel vaginal application of tamoxifen, the well-known and well-characterized selective estrogen receptor modulator (SERM), and is being developed by Daré as an alternative to estrogen-based therapies for the treatment of vulvar and vaginal atrophy (VVA) in women with or at risk for hormone-receptor positive (HR+) breast cancer.
If you want to know who really controls Daré Bioscience, Inc. (NASDAQ:DARE), then you'll have to look at the makeup of...
Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the completion of a content validity study, a non-interventional study integral to initiating the at-home, product dosing portion of the Sildenafil Cream, 3.6% (Sildenafil Cream) Phase 2b program. Daré plans to review the findings of the content validity study with the U.S. Food and Drug Administration (FDA) in a Type C meeting and to seek alignment on the patient reported outcome (PRO) instruments to be used to screen eligible patients with Female Sexual Arousal Disorder (FSAD) and to assess the efficacy of Sildenafil Cream in treating FSAD.
SAN DIEGO, Sept. 04, 2019 -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief.
SAN DIEGO, Aug. 14, 2019 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the second quarter ended June 30,.
Daré, which focuses on women's health, said Monday that its BV1 — a thermosetting hydrogel containing clindamycin phosphate 2% — has been given the Qualified Infectious Disease Product, or QIDP, designation by the FDA for the treatment of bacterial vaginosis in women. The clinical cure rates for currently approved products in bacterial vaginosis are about 37-39%, and the condition affects over 21 million among women ages 14-49, according to Daré.
Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that DARE-BV1, a novel thermosetting hydrogel containing clindamycin phosphate 2%, has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial vaginosis (BV) in women. “Receiving QIDP designation for DARE-BV1 for the treatment of BV is validation that BV is a serious infection for which current treatment options are inadequate. Our novel thermosetting hydrogel technology delivering clindamycin has the potential to become a powerful new treatment option for health care providers struggling to adequately address and resolve this persistent vaginal infection,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the presentation of a poster at the upcoming annual meeting of the Infectious Diseases Society for Obstetrics and Gynecology taking place August 8-10, 2019 in Big Sky, Montana. The poster presentation will highlight the results of an investigator-initiated, proof of concept study of DARE-BV1, a novel thermosetting bioadhesive vaginal gel technology containing clindamycin phosphate 2% for the treatment of bacterial vaginosis (BV).
SAN DIEGO, Aug. 06, 2019 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at.
The presentations will focus on recently completed studies designed to determine drug concentration and release characteristics for DARE-HRT1 and DARE-FRT1, novel intravaginal ring (IVR) drug delivery product candidates containing bio-identical hormones being developed for the treatment of menopause-related vasomotor symptoms (VMS) and luteal phase pregnancy maintenance, respectively. DARE-HRT1 is a novel, segmented ethylene-vinyl acetate (EVA) IVR delivering bioidentical 17β-estradiol and bioidentical progesterone, and DARE-FRT1 is a novel, segmented IVR delivering progesterone.
Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that it has received notification from the American Association of Pharmaceutical Scientists (AAPS) of a Best Abstract Award for the abstract titled, Vaginal Tamoxifen for Treatment of Vulvovaginal Atrophy: Pharmacokinetics and Safety in a Rabbit Model. The abstract was among the top 10% of abstracts highly ranked by AAPS Abstract Screeners.
Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, announced today that William H. Rastetter, Ph.D., a current member of its Board of Directors, was appointed Chairman of its Board of Directors effective July 11, 2019. “I believe Daré is poised to deliver on a number of significant milestones over the next 12 to 24 months. I am stepping off the board for personal reasons and fully support the company and the board changes. Bill’s wealth of experience and formidable track record of success in biotech will be instrumental in guiding Daré through its next stage of growth, and I look forward to following the company’s developments,” said Roger Hawley. Among his other awards and recognitions, Dr. Rastetter won the Biotechnology Heritage Award in 2018, an award that recognizes individuals who have made significant contributions to the development of biotechnology through discovery, innovation, and public understanding, for his work as co-inventor of Rituxan®, the first monoclonal antibody (MAb) approved by the U.S. FDA for cancer therapy.
It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...
Ovaprene is a self-administered, hormone-free, novel intravaginal ring, similar in size and shape to NuvaRing®. Ovaprene is designed to achieve contraceptive effectiveness over multiple weeks without the use of hormones and has the potential to be a first-in-category contraceptive, if approved. There currently is no FDA-approved, self-administered contraceptive that can provide month-to-month contraceptive protection without the use of hormones. This unique dual approach of a physical barrier and spermiostatic environment is designed to provide a contraceptive effect consistent with the most effective barrier option, the diaphragm, and commonly used short-acting hormonal options (contraceptive pill, patches and vaginal ring), which provide 88-91% effectiveness in “typical use.” All other commonly used or soon to be marketed hormone-free contraceptive products are used at, or shortly before, coitus (including condoms, spermicides, multi-purpose gels) and do not achieve “typical use” contraceptive effectiveness comparable to hormonal methods or are not self-administered (long-acting copper IUDs).
Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced positive findings from an investigational study designed to evaluate the feasibility of using thermography technology to assess the pharmacodynamics of Sildenafil Cream, 3.6% (Sildenafil Cream) in normal healthy women. Sildenafil is the active ingredient in a tablet for oral administration marketed under the brand name Viagra®, which is indicated for the treatment of erectile dysfunction (ED) in men. Daré Bioscience, in collaboration with Strategic Science & Technologies, LLC (SST), is developing Sildenafil Cream as a potential treatment for female sexual arousal disorder (FSAD), a condition analogous to ED in men. Sildenafil Cream is a topically administered formulation of sildenafil designed to increase local blood flow and provide a potential improvement in genital arousal response and overall sexual experience for women.
Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive Officer, will present at the 2019 BIO International Convention on Tuesday, June 4, 2019, starting at 11:15 a.m. Eastern Time in Philadelphia, PA. The BIO International Convention brings together the global biotechnology and pharmaceutical industry and is expected to include over 500 education sessions and networking opportunities with 16,000+ attendees from 67 countries. The theme for the 2019 BIO International Convention is “It Starts with One,” to highlight the critical daily contributions that combine to bring new breakthroughs to the world, and the women and men who bring new ideas and perspectives to the forefront.
R&D expense, including license fees, was $1.8M, compared to $1.2M and $1.9M in the prior-year and three-month periods, respectively. We note that Q1 expenses included $113k accrual associated with the license fees related to DARE-BV1, DARE’s new bacterial vaginosis candidate. The year-earlier period did not include any license-related expenses while the quarter-earlier period did include $275k in license fees.
Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today reported financial results for the first quarter ended March 31, 2019 and provided a Company update. “We believe our differentiated product candidate portfolio is well poised to drive value in 2019 and 2020 as we seek to execute against clinical and regulatory milestones, particularly with our Phase 3 and Phase 2 candidates. During the first quarter, we continued enrollment in the postcoital test clinical trial of Ovaprene, our monthly, non-hormonal contraceptive candidate, and we remain on track to report top-line data in the second half of 2019.
Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the article entitled “Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep” was published online in the journal Drug Delivery and Translational Research. The goal of the research was to characterize the in vitro release, pharmacokinetics and local tolerability of DARE-FRT1, a novel ethylene-vinyl acetate intravaginal ring (IVR) drug delivery technology delivering progesterone, in drug-naïve ovariectomized female Dorset crossbred sheep. DARE-FRT1 is being developed as an optimized IVR technology capable of delivering bio-identical progesterone hormone for the prevention of preterm birth (PTB), and for pregnancy maintenance and support as part of an assistive reproductive technology (ART) procedure. DARE-FRT1 is designed to allow for convenient non-invasive, non-oral administration of bio-identical progesterone over a 14-day period.
SAN DIEGO, May 07, 2019 -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast.
Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced Ovaprene’s inclusion in a presentation to physicians on the latest forms of novel contraception. Ovaprene is Daré’s clinical stage, non-hormonal vaginal ring designed to provide multiple weeks of contraceptive protection. The presentation entitled, “Contraception 2019: What about LARC, Rings, Gel, even Apps?”, was given by noted physician and women’s health expert Dr. James A. Simon during the Survival Skills for Today’s Gynecologist continuing medical education conference in New York City on Sunday, April 14th.
By Brian Marckx, CFA NASDAQ:DARE READ THE FULL DARE RESEARCH REPORT Q4 / Pipeline Update Daré Bioscience (NASDAQ:DARE) reported financial results for their fourth quarter and provided an operational update. ...